We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4004:TSEResonac Holdings Corporation Analysis

Data as of 2026-06-18 - not real-time

¥18,420.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Resonac Holdings is trading well above its 20‑day moving average, which itself sits above the 50‑day average, underscoring a bullish price momentum. The 14‑day RSI sits in the mid‑50s, indicating neither overbought nor oversold conditions. However, the MACD line remains below its signal line, producing a bearish histogram that warns of potential short‑term weakness. Volume trends are declining, suggesting waning buying interest despite the overall bullish trend direction. The stock’s valuation metrics are extreme, with a trailing P/E well above one hundred and a price‑to‑book multiple approaching five, pointing to an overvalued market price. Analyst consensus remains positive, with a “buy” rating and a modest upside potential of roughly seven percent.
The company’s fundamentals show a revenue contraction and thin profit margins, while debt levels dwarf equity, raising concerns about financial resilience. Dividend yield is low and the payout ratio, though below fifty percent, sits on a balance sheet burdened by high leverage. Volatility is elevated, with a 30‑day swing exceeding seventy percent and a beta above one, indicating sensitivity to market moves. Sector‑specific risks include cyclical demand in chemicals and heightened regulatory scrutiny on environmental matters. Geographic exposure is concentrated in Japan, adding a medium‑level country risk. Given these mixed signals, investors should weigh the bullish technical backdrop against the substantial valuation and risk considerations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD crossover
  • decreasing volume
  • price approaching resistance

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • bullish SMA alignment
  • analyst consensus buy
  • potential upside to target price

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • high valuation multiples
  • elevated debt‑to‑equity
  • persistent volatility

Key Metrics & Analysis

Financial Health

Revenue Growth-4.10%
Profit Margin2.67%
P/E Ratio114.4
ROE5.47%
ROA1.63%
Debt/Equity130.53
P/B Ratio4.7

Technical Analysis

TrendBullish
RSI57.7
Support¥14,505.00
Resistance¥20,195.00
MA 20¥17,889.75
MA 50¥15,926.70
MA 200¥9,435.03
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Target Price¥19,741.67
Upside/Downside7.18%
GradeOvervalued
TypeValue
Dividend Yield0.36%

Risk Assessment

Beta1.11
Volatility75.63%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.